You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mismatch

Showing 1 - 25 of 1,213
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H Colorectal Cancer Trial (colorectal resection)

Completed
  • MSI-H Colorectal Cancer
  • colorectal resection
  • (no location specified)
May 22, 2023

Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

Not yet recruiting
  • Endometrial Neoplasms
  • Endometrial Cancer
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
Mar 21, 2023

Stress Disorders, Post-Traumatic Trial in Charlestown (Memory reactivation procedures, Propranolol)

Not yet recruiting
  • Stress Disorders, Post-Traumatic
  • Charlestown, Massachusetts
    Massachusetts General Hospital Home Base Program
May 2, 2023

Tau PET/CT Imaging in Mismatch Prospective Cohort Study

Recruiting
  • Alzheimer's Disease
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 6, 2023

Cochlear Implant Trial in Montpellier (logatoms test, Electroencephalography)

Recruiting
  • Cochlear Implant
  • logatoms test
  • Electroencephalography
  • Montpellier, France
    CHU Montpellier
Jan 13, 2023

V/Q Mismatch as Predictor of Pulmonary Postoperative

Completed
  • Anesthesia
  • +2 more
  • Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)
  • Ferrara, Italy
    Azienda Ospedaliero Universitaria Sant'Anna
Jul 8, 2022

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

Recruiting
  • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
  • Kashiwa, Chiba, Japan
    Novartis Investigative Site
May 2, 2023

Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,

Not yet recruiting
  • Adenocarcinoma of the Stomach
  • +2 more
  • Hangzhou, Zhejiang, China
  • +4 more
May 23, 2023

To Improve Speech Understanding in Noise and Localization in SSD-CI Recipients Trial in Saint Louis (Treatment-modifications to

Recruiting
  • To Improve Speech Understanding in Noise and Localization in SSD-CI Recipients
  • Treatment-modifications to CI speech processor program
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 8, 2022

Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

Recruiting
  • Recurrent Endometrial Cancer
  • Solid Tumors
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 12, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer Trial in Houston (Tecentriq 1200 MG in 20 ML Injection +

Not yet recruiting
  • Stage I Colon Cancer
  • +2 more
  • Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
  • +2 more
  • Houston, Texas
    Baylor College of Medicine
May 22, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Immunological Pure Red Cell Aplasia Trial (Isatuximab)

Not yet recruiting
  • Immunological Pure Red Cell Aplasia
  • (no location specified)
Sep 26, 2022

Allogenomic Mismatch Score Applied to Haplo-identical

Completed
  • Stem Cell Transplantation
  • Haplo-identical
  • Assessment of the Allogenomic Mismatch Score (AMS)
  • Assessment of the optimised Allogenomic Mismatch Score (AMS)
  • Vandœuvre-lès-Nancy, France
    Alice Aarnink
Feb 7, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer Trial in Richmond (Lenvatinib, Pembrolizumab)

Recruiting
  • Endometrial Cancer
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University
Apr 5, 2022

Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,

Recruiting
  • Epstein-Barr Virus Positive
  • +10 more
  • Atlanta, Georgia
  • +2 more
Dec 10, 2022

Schizophrenia Trial in New York (CVN058, Placebos)

Completed
  • Schizophrenia
  • New York, New York
  • +2 more
Aug 4, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Autism Spectrum Disorder, Fragile X Syndrome Trial (Mismatch negativity)

Not yet recruiting
  • Autism Spectrum Disorder
  • Fragile X Syndrome
  • Mismatch negativity
  • (no location specified)
Oct 12, 2023

Anal Squamous Cell Carcinoma, Colorectal Tumors, Soft Tissue Sarcoma Trial (Regorafenib in combination with Tislelizumab)

Not yet recruiting
  • Anal Squamous Cell Carcinoma
  • +7 more
  • Regorafenib in combination with Tislelizumab
  • (no location specified)
Oct 12, 2022

ARDS, Human Trial in Nanjing (PEEP selection)

Recruiting
  • ARDS, Human
  • PEEP selection
  • Nanjing, Jiangsu, China
    Zhongda Hospital, School of Medicine, Southeast University
Feb 9, 2023

Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 22, 2022

Kidney Transplant Rejection Trial (MDR-103)

Not yet recruiting
  • Kidney Transplant Rejection
  • MDR-103
  • (no location specified)
Apr 4, 2022